File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema

TitleLong-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
Authors
KeywordsAge-related macular degeneration
Anti-VEGF therapy
Cost-effectiveness
Diabetic macular edema
Diabetic retinopathy
Ranibizumab
Safety
Issue Date2013
Citation
Clinical Interventions in Aging, 2013, v. 8, p. 467-483 How to Cite?
AbstractNeovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) are major causes of visual impairment in the elderly population worldwide. With the aging population, the prevalence of neovascular AMD and DME has increased substantially over the recent years. Vascular endothelial growth factor (VEGF) has been implicated as playing an important role in the pathogenesis of both neovascular AMD and DME. Since its introduction in 2006, ranibizumab, a recombinant, humanized, monoclonal antibody fragment against all isoforms of VEGF-A, has revolutionized the treatment of neovascular AMD and DME. The efficacy and safety of ranibizumab in neovascular AMD has been demonstrated in the ANCHOR and MARINA trials. Further studies including the PIER, PrONTO, and SUSTAIN trials have also evaluated the optimal dosing regimen of ranibizumab in neovascular AMD. The CATT and IVAN trials compared the safety and efficacy of ranibizumab with off-label use of bevacizumab. Studies such as SUSTAIN and HORIZON have shown that ranibizumab has a good safety profile and is well tolerated for over 4 years with very few serious ocular and systemic adverse events. For DME, Phase II RESOLVE study and Phase III RISE and RIDE studies have demonstrated superiority of ranibizumab treatment in improving vision over placebo controls. Phase II READ and Phase III RESOLVE and REVEAL studies have shown that ranibizumab is more effective both as monotherapy and in combination with laser compared with laser monotherapy. The 3-year results from the DRCRnet protocol I study found that ranibizumab with deferred laser resulted in better long-term visual outcome compared with ranibizumab with prompt laser. This review summarizes various important clinical trials on the long-term efficacy and safety of ranibizumab in the treatment of neovascular AMD and DME. The pharmacological properties of ranibizumab, its cost effectiveness, and impact on quality of life will also be discussed. © 2013 Fong and Lai, publisher and licensee Dove Medical Press Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/335757
ISSN
2013 Impact Factor: 1.824
2023 SCImago Journal Rankings: 0.893
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorFong, Angie H.C.-
dc.contributor.authorLai, Timothy Y.Y.-
dc.date.accessioned2023-12-28T08:48:31Z-
dc.date.available2023-12-28T08:48:31Z-
dc.date.issued2013-
dc.identifier.citationClinical Interventions in Aging, 2013, v. 8, p. 467-483-
dc.identifier.issn1176-9092-
dc.identifier.urihttp://hdl.handle.net/10722/335757-
dc.description.abstractNeovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) are major causes of visual impairment in the elderly population worldwide. With the aging population, the prevalence of neovascular AMD and DME has increased substantially over the recent years. Vascular endothelial growth factor (VEGF) has been implicated as playing an important role in the pathogenesis of both neovascular AMD and DME. Since its introduction in 2006, ranibizumab, a recombinant, humanized, monoclonal antibody fragment against all isoforms of VEGF-A, has revolutionized the treatment of neovascular AMD and DME. The efficacy and safety of ranibizumab in neovascular AMD has been demonstrated in the ANCHOR and MARINA trials. Further studies including the PIER, PrONTO, and SUSTAIN trials have also evaluated the optimal dosing regimen of ranibizumab in neovascular AMD. The CATT and IVAN trials compared the safety and efficacy of ranibizumab with off-label use of bevacizumab. Studies such as SUSTAIN and HORIZON have shown that ranibizumab has a good safety profile and is well tolerated for over 4 years with very few serious ocular and systemic adverse events. For DME, Phase II RESOLVE study and Phase III RISE and RIDE studies have demonstrated superiority of ranibizumab treatment in improving vision over placebo controls. Phase II READ and Phase III RESOLVE and REVEAL studies have shown that ranibizumab is more effective both as monotherapy and in combination with laser compared with laser monotherapy. The 3-year results from the DRCRnet protocol I study found that ranibizumab with deferred laser resulted in better long-term visual outcome compared with ranibizumab with prompt laser. This review summarizes various important clinical trials on the long-term efficacy and safety of ranibizumab in the treatment of neovascular AMD and DME. The pharmacological properties of ranibizumab, its cost effectiveness, and impact on quality of life will also be discussed. © 2013 Fong and Lai, publisher and licensee Dove Medical Press Ltd.-
dc.languageeng-
dc.relation.ispartofClinical Interventions in Aging-
dc.subjectAge-related macular degeneration-
dc.subjectAnti-VEGF therapy-
dc.subjectCost-effectiveness-
dc.subjectDiabetic macular edema-
dc.subjectDiabetic retinopathy-
dc.subjectRanibizumab-
dc.subjectSafety-
dc.titleLong-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2147/CIA.S36811-
dc.identifier.pmid23766636-
dc.identifier.scopuseid_2-s2.0-84876964702-
dc.identifier.volume8-
dc.identifier.spage467-
dc.identifier.epage483-
dc.identifier.eissn1178-1998-
dc.identifier.isiWOS:000318148800001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats